LIVN — LivaNova PLC stock price, charts and financials

QT75LivaNova PLC

LivaNova PLC (NASDAQ: LIVN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
76.12
-0.10-0.13%
OverviewShort InterestFilings
LIVNQT75LivaNova PLC·NASDAQ
76.12-0.13%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IRTC-2.02%$125.26ITGR-0.16%$125.07HAE-1.74%$86.31TMDX+3.02%$86.42AXGN+1.92%$47.32UFPT+1.57%$318.93BFLY+11.72%$9.87ESTA-0.98%$76.66
Snapshot
Index-P/E22.09EPS (ttm)3.45Insider Own1.13%Shs Outstand54.93MPerf Week-4.89%
Market Cap4.19BForward P/E16.28EPS next Y4.68Insider Trans-0.48%Shs Float54.70MPerf Month-7.63%
Enterprise Value4.02BPEG0.08EPS next Q-Inst Own-Short Float7.47%Perf Quarter7.46%
Income188.42MP/S2.85EPS this Y121.52%Inst Trans-Short Ratio5.11Perf Half Y17.21%
Sales1.47BP/B3.16EPS next Y7.84%ROA7.14%Short Interest4.09MPerf YTD23.87%
Book/sh-P/C15.85EPS next 5Y19.92%ROE15.41%52W High85.64 -11.12%Perf Year60.94%
Cash/sh-P/FCF28.05EPS past 3/5Y-ROIC10.19%52W Low47.07 61.72%Perf 3Y32.65%
Dividend Est.-EV/EBITDA22.26Sales past 3/5Y10.74% 8.25%Gross Margin68.18%Volatility4.19% 3.14%Perf 5Y-11.68%
Dividend TTM-EV/Sales2.73EPS Y/Y TTM68.97%Oper. Margin13.48%ATR (14)2.88Perf 10Y47.43%
Dividend Ex-Date-Quick Ratio1.21Sales Y/Y TTM14.45%Profit Margin12.82%RSI (14)41.55Recom2.33
Dividend Gr. 3/5Y-Current Ratio1.45EPS Q/Q11.36%SMA20-4.81%Beta0.85Target Price87.67
Payout0.00%Debt/Eq0.27Sales Q/Q14.20%SMA50-3.93%Rel Volume1.02Prev Close76.22
Employees3,300LT Debt/Eq0.37EarningsNov 04SMA20013.57%Avg Volume733.86KPrice76.12
IPO DateOct 19, 2015Option/ShortYes / YesEPS/Sales Surpr.9.30% 4.69%Net Debt/EBITDA-0.91Volume744,982Change-0.13%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedStifel NicolausBuy$80 → $85
Aug-05-26ReiteratedNeedhamBuy$81 → $93
Jul-15-26ReiteratedMizuhoOutperform$90 → $95
Jun-22-26ReiteratedKeybancOverweight$81 → $92
May-07-26ReiteratedMizuhoOutperform$72 → $90
May-07-26ReiteratedBarclaysEqual Weight$67 → $76
Feb-25-26ReiteratedStifel NicolausBuy$70 → $80
Feb-25-26ReiteratedNeedhamBuy$88 → $81
Feb-19-26ReiteratedPiper SandlerOverweight$85
Jan-09-26ReiteratedGoldman SachsBuy$56 → $66
Latest News
Aug-06-26
Aug-06-2601:36PM
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raisedzacks.com
Aug-05-26
Aug-05-2601:30PM
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcriptseekingalpha.com
01:05PM
LivaNova Q2 Earnings Call Highlightsmarketbeat.com
10:31AM
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com
10:16AM
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?zacks.com
08:26AM
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimateszacks.com
06:00AM
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidancebusinesswire.com
03:05AM
Amundi Cuts Stock Position in LivaNova PLC $LIVNdefenseworld.net
Jul-28-26
Jul-28-2603:15AM
Bank of New York Mellon Corp Sells 206,050 Shares of LivaNova PLC $LIVNdefenseworld.net
Jul-27-26
Jul-27-2612:40PM
LivaNova (NASDAQ:LIVN): A Strong Growth Stock with a Constructive Technical SetupChartMill
Jul-21-26
Jul-21-2609:30AM
LivaNova (NASDAQ:LIVN) Fits the Affordable Growth Profile with Strong Earnings and Relative ValueChartMill
Jul-17-26
Jul-17-2611:26AM
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdleszacks.com
Jul-15-26
Jul-15-2602:31PM
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $95Benzinga
Jul-07-26
Jul-07-2610:20AM
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?zacks.com
Jun-24-26
Jun-24-2601:00PM
LivaNova to Announce Second-Quarter 2026 ResultsYahoo
Company

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,4721,3881,253——————
Cost of Goods Sold Incl. D&A468448383——————
Gross Profit1,004940871——————
Selling, General and Administrative Excl. Other584549526——————
Research and Development204186183——————
Other Operating Expense17633——————
Operating Income199199129——————
Interest Expense464963——————
Unusual Expense
—————————
Non-Operating Income (Expense)-45-37122——————
Net Income Before Taxes108-22188——————
Income Taxes-822225——————
Consolidated Net Income189-24263——————
Net Income From Continuing Operations189-24263——————
Net Income189-24263——————
EPS (Recurring)3.45-4.451.17——————
EPS (Basic, Before Extraordinaries)3.45-4.451.17——————
EPS (Diluted)3.39-4.451.16——————
EBITDA181-129203——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio22.45—39.92——————
Price To Sales Ratio2.842.442.00——————
Gross Margin68.2167.7269.51——————
Operating Margin13.5214.3410.30——————
Net Margin12.84-17.445.03——————
Shares Outstanding555554——————
Market Capitalization4,1873,3842,501——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$91.96$77.59$63.23$48.86$34.50● Close Price0.00K34.09K68.17K102.26K136.35KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
WILVER PETER MDirectorJun 15 '26Option Exercise0.004,042010,780Jun 17
SCHERMERHORN TODD CDirectorJun 15 '26Option Exercise0.004,042013,105Jun 17
Bianchi FrancescoDirectorJun 15 '26Option Exercise0.004,042011,270Jun 17
Bianchi FrancescoDirectorJun 15 '26Sale80.191,20096,2289,584Jun 17
PODLOGAR SUSAN MDirectorJun 15 '26Option Exercise0.004,04206,128Jun 17
Barry James ChristopherDirectorJun 15 '26Option Exercise0.004,04208,404Jun 17
Tezel AhmetChief Innovation OfficerJun 15 '26Option Exercise0.002,96507,122Jun 17
KOZY WILLIAM ADirectorJun 15 '26Option Exercise0.005,681038,248Jun 17
Enxing Seng StacyDirectorJun 15 '26Option Exercise0.004,042015,793Jun 17
Story BrookeDirectorJun 15 '26Option Exercise0.004,042010,274Jun 17
Zurbay DonaldDirectorJun 15 '26Option Exercise0.002,56002,560Jun 17
Bianchi FrancescoDirectorMay 26 '26Sale75.751,800136,3507,228May 27
Tezel AhmetChief Innovation OfficerMar 30 '26Option Exercise0.003,40805,343Apr 01
Poletti FrancoPresident, CardiopulmonaryMar 30 '26Option Exercise0.006,368012,125Apr 01
Shvartsburg AlexChief Financial OfficerMar 30 '26Option Exercise0.0050,290057,515Apr 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.